Insys Therapeutics Inc (INSY) 29.78 $INSY
Insys Therapeutics, Inc. to Present at Jefferies Autumn 2015 Global Healthcare Conference
GlobeNewswire - Thu Nov 12, 7:00AM CST
Insys Therapeutics, Inc. ("Insys" or "the Company"
(NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, will present at the Jefferies Autumn 2015 Global Healthcare Conference as follows:
INSY: 29.78 (+1.14)
Why Insys Therapeutics Shares Dropped Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 11, 5:28PM CST
Source: Insys Therapeutics What: News that the nation's largest pharmacy benefit manager is severing ties with a specialty pharmacy that fills prescriptions for it and a competitor sent shares in Insys Therapeutics tumbling by 10% earlier...
INSY: 29.78 (+1.14), TEVA: 60.13 (+1.32)
Here's Why Galena Biopharma's Stock Tanked Today
George Budwell, The Motley Fool - Motley Fool - Tue Nov 10, 11:56AM CST
Source: Orexo What : Shares of Galena Biopharma , a cancer immunotherapy company, nosedived today following the company's third quarter earnings release. What appears to have struck a sour note with investors is the company's decision to...
INSY: 29.78 (+1.14), GALE: 1.47 (unch)
GTSO: U.S. Cannabis Market Expands to Illinois
Business Wire - Tue Nov 10, 4:00AM CST
Green Technology Solutions, Inc. (OTCBB: GTSO) remains hard at work developing and marketing new solutions for cannabis businesses across the country as the emerging industry continues to expand rapidly. On Monday, Illinois became the 23rd state to open state-licensed dispensaries selling medical cannabis.
INSY: 29.78 (+1.14)
NTRR Leadership Explores New Business Opportunities at America's Largest Cannabis Trade Show
Business Wire - Tue Nov 10, 4:00AM CST
Neutra Corp.'s (OTCBB: NTRR) executive leadership will travel to Las Vegas this week to explore new innovations and business opportunities at the 2015 Marijuana Business Conference and Expo--the nation's premier cannabis industry networking event.
INSY: 29.78 (+1.14)
Will Allegations Derail Insys' Rapid Sales Growth?
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 08, 9:20AM CST
Source: Insys Therapeutics. Insys Therapeutics has been the subject of controversy since the Department of Health and Human Services contacted it in 2013 requesting insight into commercialization efforts tied to Subsys, its fast-acting opioid...
INSY: 29.78 (+1.14)
Seizures Pipeline Review, H2 2015
M2 - Fri Nov 06, 9:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/qz6j88/seizures) has announced the addition of the "Seizures - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advicenne Pharma - Alexza Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Eisai Co., Ltd. - GW Pharmaceuticals Plc - H. Lundbeck A/S - INSYS Therapeutics, Inc. - Ligand Pharmaceuticals, Inc. - Marathon Pharmaceuticals, LLC - Marinus Pharmaceuticals, Inc. - Novartis AG - OPKO Health, Inc. - Retrophin Inc. - Sage Therapeutics - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - UCB S.A. - Ultragenyx Pharmaceutical Inc. - Upsher-Smith Laboratories, Inc. - Xenon Pharmaceuticals Inc. - Zogenix, Inc. For more information visit http://www.researchandmarkets.com/research/qz6j88/seizures
INSY: 29.78 (+1.14), OPK: 10.74 (+0.11), MRNS: 5.27 (+0.17), CPRX: 2.69 (-0.12), ZGNX: 13.00 (-0.46), XENE: 8.11 (+0.11), RTRX: 18.47 (+0.10), ALXA: 1.04 (+0.03), NVS: 87.48 (+0.43)
Insys CEO Babich resigns, drugmaker tops 3Q expectations
By The Associated Press - AP - Thu Nov 05, 8:48AM CST
Michael L. Babich has resigned as president and CEO of Insys Therapeutics, a specialty drugmaker under investigation over sales of its powerful painkiller Subsys.
INSY: 29.84 (+1.20)
GTSO: Edibles Recall Highlights Need for Newer, Better Cannabis Solutions
Business Wire - Thu Nov 05, 7:52AM CST
As demand grows for greater precautions and regulations in the booming U.S. cannabis industry, products in Colorado were recalled this week due to contamination by potentially harmful pesticides used during cultivation. Green Technology Solutions, Inc. (OTCBB: GTSO) is working to market and develop new technologies to calm consumer anxieties and help avoid such costly recalls in the future.
INSY: 29.84 (+1.20)
Insys Therapeutics Announces Stock Repurchase Program
GlobeNewswire - Thu Nov 05, 5:52AM CST
Insys Therapeutics, Inc. (Nasdaq:INSY) ("Insys" or "the Company" today announced that its Board of Directors has approved the repurchase of up to $50 million of the Company's common stock.
INSY: 29.81 (+1.17)
Insys Therapeutics Announces Senior Management Changes and Appointments
GlobeNewswire - Thu Nov 05, 5:51AM CST
Michael Babich Departs as Insys President and CEO
INSY: 29.81 (+1.17)
Insys Therapeutics Reports Record Third Quarter 2015 Results
GlobeNewswire - Thu Nov 05, 5:50AM CST
Announces Senior Management Changes and Appointments
INSY: 29.81 (+1.17)
NTRR: Latest Colorado Edibles Recall Underscores Growing Market for Pesticide Alternatives
Business Wire - Thu Nov 05, 4:00AM CST
A recall of cannabis edibles products in Colorado this month underscores a growing demand for alternatives to harsh chemicals used to control pests in the U.S. cannabis industry, and Neutra Corp. (OTCBB: NTRR) is helping to deliver these new solutions to a hungry marketplace.
INSY: 29.81 (+1.17)
5 Hated Stocks You Should Love
at The Street - Tue Nov 03, 10:51AM CST
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
INSY: 29.81 (+1.17), FNGN: 32.96 (-0.57), SHAK: 42.29 (-1.13), FMI: 16.26 (-0.25), TRUE: 7.00 (-0.04)
NTRR Readies Products for New Market Opportunities as Ohio Votes on Cannabis Legalization
Business Wire - Tue Nov 03, 4:00AM CST
Horticulture technology innovator Neutra Corp. (OTCBB:NTRR) looks forward to more new business opportunities opening up today as Ohio becomes the latest state to vote on the legalization of cannabis.
INSY: 29.81 (+1.17)
Insys Therapeutics Announces Its Naloxone Sublingual Spray Received Fast Track Designation From the FDA for the Treatment of Opioid Intoxication or Overdose
Marketwired - Thu Oct 29, 2:04PM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company" today announced that the U.S. Food and Drug Administration ("FDA" has granted Fast Track designation to its Naloxone Sublingual Spray for the treatment of known or suspected opioid intoxication or overdose.
INSY: 29.81 (+1.17)
GTSO Works to Develop Innovative New Packaging to Keep Kids Safe From Cannabis Edibles
Business Wire - Thu Oct 29, 4:00AM CDT
The U.S. market for cannabis edibles is exploding nationwide, and alongside its joint venture partners, Green Technology Solutions, Inc. (OTCBB:GTSO) is developing a suite of new edibles products to capitalize on the rising popularity of edibles. But the company is also hard at work on innovative new packaging ideas designed to keep cannabis edibles safely away from children.
INSY: 29.81 (+1.17)
NTRR Partner Prepares to Begin Plant Enhancer Case Study at Cannabis Farm in Hawaii
Business Wire - Wed Oct 28, 4:23AM CDT
The U.S. cannabis industry is booming nationwide, creating more and more demand for the unique suite of horticultural products supplied by Neutra Corp. (OTCBB: NTRR) and its joint venture partners. This week, the company is preparing to begin a new case study on its plant enhancer on a medical cannabis farm in the state of Hawaii.
INSY: 29.81 (+1.17)
Insys Therapeutics Issues Statement on Its Use of Specialty Pharmacies
Marketwired - Mon Oct 26, 1:57PM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company" today issued a statement on the Company's use of specialty pharmacies:
INSY: 29.81 (+1.17)
RBC Capital Markets Says Buy These 5 Pharmaceutical Stocks, Despite 'Irrational' Sell Off
at The Street - Thu Oct 22, 9:46AM CDT
The selloff in specialty pharmaceutical stocks has found a new "irrational low," following Wednesday's attack on Valeant Pharmaceuticals, according to RBC Capital Markets.
AGN: 296.35 (-2.36), ENDP: 58.00 (+1.10), INSY: 29.81 (+1.17), VRX: 70.41 (-2.91), SGNT: 14.75 (-0.64), IBB: 328.57 (+3.68), TEVA: 60.13 (+1.32)
Insys Therapeutics, Inc. to Present at Jefferies Autumn 2015 Global Healthcare Conference
GlobeNewswire - Thu Nov 12, 7:00AM CST
Insys Therapeutics, Inc. ("Insys" or "the Company"
(NASDAQ:INSY) today announced that Darryl Baker, Chief Financial Officer, will present at the Jefferies Autumn 2015 Global Healthcare Conference as follows: INSY: 29.78 (+1.14)
Why Insys Therapeutics Shares Dropped Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 11, 5:28PM CST
Source: Insys Therapeutics What: News that the nation's largest pharmacy benefit manager is severing ties with a specialty pharmacy that fills prescriptions for it and a competitor sent shares in Insys Therapeutics tumbling by 10% earlier...
INSY: 29.78 (+1.14), TEVA: 60.13 (+1.32)
Here's Why Galena Biopharma's Stock Tanked Today
George Budwell, The Motley Fool - Motley Fool - Tue Nov 10, 11:56AM CST
Source: Orexo What : Shares of Galena Biopharma , a cancer immunotherapy company, nosedived today following the company's third quarter earnings release. What appears to have struck a sour note with investors is the company's decision to...
INSY: 29.78 (+1.14), GALE: 1.47 (unch)
GTSO: U.S. Cannabis Market Expands to Illinois
Business Wire - Tue Nov 10, 4:00AM CST
Green Technology Solutions, Inc. (OTCBB: GTSO) remains hard at work developing and marketing new solutions for cannabis businesses across the country as the emerging industry continues to expand rapidly. On Monday, Illinois became the 23rd state to open state-licensed dispensaries selling medical cannabis.
INSY: 29.78 (+1.14)
NTRR Leadership Explores New Business Opportunities at America's Largest Cannabis Trade Show
Business Wire - Tue Nov 10, 4:00AM CST
Neutra Corp.'s (OTCBB: NTRR) executive leadership will travel to Las Vegas this week to explore new innovations and business opportunities at the 2015 Marijuana Business Conference and Expo--the nation's premier cannabis industry networking event.
INSY: 29.78 (+1.14)
Will Allegations Derail Insys' Rapid Sales Growth?
Todd Campbell, The Motley Fool - Motley Fool - Sun Nov 08, 9:20AM CST
Source: Insys Therapeutics. Insys Therapeutics has been the subject of controversy since the Department of Health and Human Services contacted it in 2013 requesting insight into commercialization efforts tied to Subsys, its fast-acting opioid...
INSY: 29.78 (+1.14)
Seizures Pipeline Review, H2 2015
M2 - Fri Nov 06, 9:49AM CST
Research and Markets (http://www.researchandmarkets.com/research/qz6j88/seizures) has announced the addition of the "Seizures - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advicenne Pharma - Alexza Pharmaceuticals, Inc. - Catalyst Pharmaceutical Partners, Inc. - Eisai Co., Ltd. - GW Pharmaceuticals Plc - H. Lundbeck A/S - INSYS Therapeutics, Inc. - Ligand Pharmaceuticals, Inc. - Marathon Pharmaceuticals, LLC - Marinus Pharmaceuticals, Inc. - Novartis AG - OPKO Health, Inc. - Retrophin Inc. - Sage Therapeutics - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - UCB S.A. - Ultragenyx Pharmaceutical Inc. - Upsher-Smith Laboratories, Inc. - Xenon Pharmaceuticals Inc. - Zogenix, Inc. For more information visit http://www.researchandmarkets.com/research/qz6j88/seizures
INSY: 29.78 (+1.14), OPK: 10.74 (+0.11), MRNS: 5.27 (+0.17), CPRX: 2.69 (-0.12), ZGNX: 13.00 (-0.46), XENE: 8.11 (+0.11), RTRX: 18.47 (+0.10), ALXA: 1.04 (+0.03), NVS: 87.48 (+0.43)
Insys CEO Babich resigns, drugmaker tops 3Q expectations
By The Associated Press - AP - Thu Nov 05, 8:48AM CST
Michael L. Babich has resigned as president and CEO of Insys Therapeutics, a specialty drugmaker under investigation over sales of its powerful painkiller Subsys.
INSY: 29.84 (+1.20)
GTSO: Edibles Recall Highlights Need for Newer, Better Cannabis Solutions
Business Wire - Thu Nov 05, 7:52AM CST
As demand grows for greater precautions and regulations in the booming U.S. cannabis industry, products in Colorado were recalled this week due to contamination by potentially harmful pesticides used during cultivation. Green Technology Solutions, Inc. (OTCBB: GTSO) is working to market and develop new technologies to calm consumer anxieties and help avoid such costly recalls in the future.
INSY: 29.84 (+1.20)
Insys Therapeutics Announces Stock Repurchase Program
GlobeNewswire - Thu Nov 05, 5:52AM CST
Insys Therapeutics, Inc. (Nasdaq:INSY) ("Insys" or "the Company"
today announced that its Board of Directors has approved the repurchase of up to $50 million of the Company's common stock. INSY: 29.81 (+1.17)
Insys Therapeutics Announces Senior Management Changes and Appointments
GlobeNewswire - Thu Nov 05, 5:51AM CST
Michael Babich Departs as Insys President and CEO
INSY: 29.81 (+1.17)
Insys Therapeutics Reports Record Third Quarter 2015 Results
GlobeNewswire - Thu Nov 05, 5:50AM CST
Announces Senior Management Changes and Appointments
INSY: 29.81 (+1.17)
NTRR: Latest Colorado Edibles Recall Underscores Growing Market for Pesticide Alternatives
Business Wire - Thu Nov 05, 4:00AM CST
A recall of cannabis edibles products in Colorado this month underscores a growing demand for alternatives to harsh chemicals used to control pests in the U.S. cannabis industry, and Neutra Corp. (OTCBB: NTRR) is helping to deliver these new solutions to a hungry marketplace.
INSY: 29.81 (+1.17)
5 Hated Stocks You Should Love
at The Street - Tue Nov 03, 10:51AM CST
These heavily shorted stocks could get squeezed much higher if they report positive earnings this week.
INSY: 29.81 (+1.17), FNGN: 32.96 (-0.57), SHAK: 42.29 (-1.13), FMI: 16.26 (-0.25), TRUE: 7.00 (-0.04)
NTRR Readies Products for New Market Opportunities as Ohio Votes on Cannabis Legalization
Business Wire - Tue Nov 03, 4:00AM CST
Horticulture technology innovator Neutra Corp. (OTCBB:NTRR) looks forward to more new business opportunities opening up today as Ohio becomes the latest state to vote on the legalization of cannabis.
INSY: 29.81 (+1.17)
Insys Therapeutics Announces Its Naloxone Sublingual Spray Received Fast Track Designation From the FDA for the Treatment of Opioid Intoxication or Overdose
Marketwired - Thu Oct 29, 2:04PM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company"
today announced that the U.S. Food and Drug Administration ("FDA" has granted Fast Track designation to its Naloxone Sublingual Spray for the treatment of known or suspected opioid intoxication or overdose. INSY: 29.81 (+1.17)
GTSO Works to Develop Innovative New Packaging to Keep Kids Safe From Cannabis Edibles
Business Wire - Thu Oct 29, 4:00AM CDT
The U.S. market for cannabis edibles is exploding nationwide, and alongside its joint venture partners, Green Technology Solutions, Inc. (OTCBB:GTSO) is developing a suite of new edibles products to capitalize on the rising popularity of edibles. But the company is also hard at work on innovative new packaging ideas designed to keep cannabis edibles safely away from children.
INSY: 29.81 (+1.17)
NTRR Partner Prepares to Begin Plant Enhancer Case Study at Cannabis Farm in Hawaii
Business Wire - Wed Oct 28, 4:23AM CDT
The U.S. cannabis industry is booming nationwide, creating more and more demand for the unique suite of horticultural products supplied by Neutra Corp. (OTCBB: NTRR) and its joint venture partners. This week, the company is preparing to begin a new case study on its plant enhancer on a medical cannabis farm in the state of Hawaii.
INSY: 29.81 (+1.17)
Insys Therapeutics Issues Statement on Its Use of Specialty Pharmacies
Marketwired - Mon Oct 26, 1:57PM CDT
Insys Therapeutics, Inc. (NASDAQ: INSY) ("Insys" or "the Company"
today issued a statement on the Company's use of specialty pharmacies: INSY: 29.81 (+1.17)
RBC Capital Markets Says Buy These 5 Pharmaceutical Stocks, Despite 'Irrational' Sell Off
at The Street - Thu Oct 22, 9:46AM CDT
The selloff in specialty pharmaceutical stocks has found a new "irrational low," following Wednesday's attack on Valeant Pharmaceuticals, according to RBC Capital Markets.
AGN: 296.35 (-2.36), ENDP: 58.00 (+1.10), INSY: 29.81 (+1.17), VRX: 70.41 (-2.91), SGNT: 14.75 (-0.64), IBB: 328.57 (+3.68), TEVA: 60.13 (+1.32)
